Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2011-02190 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| COG-NB-2008-01 | Other Identifier | Children's Oncology Group | |
| ANBL08B1 | Other Identifier | CTEP | |
| COG-ANBL08B1 | Other Identifier | Children's Oncology Group |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research trial studies specimens from young patients with neuroblastoma. Studying the genes expressed in specimens from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PRIMARY OBJECTIVES:
I. Establish a robust messenger ribonucleic acid (mRNA) gene expression classifier for improved outcome prediction in children with neuroblastoma by using real-time polymerase chain reaction (PCR) to quantify mRNA levels from genes that have been shown in at least 2 independent studies to have predictive power.
II. Identify microRNA (miRNA) patterns that have prognostic significance in neuroblastoma (NB) as accumulating evidence indicates that alterations in miRNA expression play a critical role in tumorigenesis and can be used in prognostic evaluation.
III. To perform an integrated analysis of the established microRNA classifier with our mRNA signature to determine whether it results in even better classification of NB tumors.
OUTLINE:
Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ancillary-Correlative (gene expression profiling) | Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| laboratory biomarker analysis | Other | Correlative studies |
|
| Measure | Description | Time Frame |
|---|---|---|
| mRNA expression levels from genes that have been shown (in at least two independent studies) to have power for outcome prediction in children with NB, assessed by real-time PCR | Multivariate logistic regression analyses will be performed to determine if the mRNA expression signature is a significant independent predictor after controlling for currently used risk factors. | Baseline |
| miRNA patterns that have prognostic significance in NB, assessed by a reverse transcription quantitative PCR-based 'stem-loop' method to quantify expression levels | Multivariate logistic regression analyses will be performed to determine if the miRNA expression signature is a significant independent predictor after controlling for currently used risk factors. | Baseline |
Not provided
Not provided
Inclusion Criteria:
Diagnosis of primary Neuroblastoma
RNA samples from primary untreated NB-tumors available in Children's Oncology Group (COG) repository
At least 2 years of follow-up from the date of diagnosis
Full clinical and biological annotation
Not provided
Not provided
Not provided
Patients With Neuroblastoma
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Hogarty, MD | Children's Oncology Group | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Oncology Group | Philadelphia | Pennsylvania | 19104 | United States |
Not provided
Not provided
Not provided
Not provided